Form 8-K Keros Therapeutics, Inc. For: Mar 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Keros Therapeutics (KROS) Announces Resignation of Chief Medical Officer
March 5, 2024 8:07 AM ESTOn February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics (NASDAQ: KROS), effective March 12, 2024, to pursue other opportunities. Dr. Coopers resignation is voluntary and is not the result of any disagreement with the... More
